Overview
Union Minister Dr. Jitendra Singh launched India's first indigenous CRISPR based gene therapy for Sickle Cell Disease, named "BIRSA 101". This therapy is dedicated to Bhagwan Birsa Munda, commemorating his 150th anniversary. The initiative marks a significant step towards achieving a Sickle Cell Disease-free India and promoting Atmanirbhar Bharat in medical technologies.
Key Developments
- Launch Date: November 19, 2025
- Therapy Name: BIRSA 101
- Developer: CSIR–Institute of Genomics & Integrative Biology (IGIB)
- Partner: Serum Institute of India (SIIPL)
- Goal: Sickle Cell Disease-free India by 2047
Significance
The development and launch of BIRSA 101 represent a major milestone in India's public health and genomic medicine landscape. This indigenous CRISPR-based gene therapy demonstrates India's capability to produce pathbreaking therapies at a fraction of global costs, potentially replacing treatments priced at ₹20–25 crore overseas. The therapy holds deep national significance, especially for tribal communities in central and eastern India, where the disease burden is highest.
Technology Transfer and Collaboration
A formal technology transfer and collaboration agreement was exchanged between CSIR-IGIB and the Serum Institute of India Pvt. Ltd. This partnership enables the translation of IGIB’s engineered enFnCas9 CRISPR platform into scalable, affordable therapies for Sickle Cell Disease and other critical genetic disorders. This collaboration mirrors India’s successful public-private model seen during the development of several vaccines and therapeutics over the past decade.
UPSC Relevance
This development is highly relevant for the UPSC Civil Services Exam, particularly under GS Paper 3 (Science and Technology) and GS Paper 2 (Health). It highlights India's advancements in biotechnology, healthcare innovation, and public-private partnerships. The focus on tribal communities also connects to social justice and inclusive development themes.
Important Facts
- Sickle Cell Disease particularly affects India's tribal population.
- BIRSA 101 is dedicated to Bhagwan Birsa Munda.
- The CRISPR platform was developed at CSIR–Institute of Genomics & Integrative Biology (IGIB).
- Serum Institute of India (SIIPL) is partnering for scalable and affordable therapies.
- The goal is to achieve a Sickle Cell Disease-free India by 2047.